Co-Director, IHV Clinical Research Unit; Division Head, Infectious Diseases
Professor of Medicine
725 W. Lombard Street
Education and Training
1991, MD - Medicine, Medical College, Trichur
1998, PhD - Immunology, Memorial University, Newfoundland
2000, Resident - Internal Medicine, Brown University, Providence, Rhode Island
2003, Fellow - Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Dr. Shyam Kottilil MD. Ph.D. is the Director of the Division of Clinical Care and Research at the Institute of Human Virology (IHV), University of Maryland, Baltimore MD. Dr. Kottilil also serves as the Director of the Clinical Trials Unit, Division of Infectious Diseases at the IHV. Dr. Kottilil is alos the Chief of the Division of Infectious Diseases at the Department of Medicine, University of Maryland School of Medicine. Dr. Kottilil continues to work as the Scientific Director of the NIH-District of Columbia Program for AIDS Progress. He received his medical degree from Govt Medical College, Trichur, India, Ph.D (immunology of HIV infection) from Memorial University of Newfoundland, Canada, completed a residency in Internal Medicine from Brown University, Rhode Island and a fellowship in infectious diseases rom the National Institutes of Health under Dr. Anthony S. Fauci.
Dr. Kottilil has conducted several pivotal investigator initiated studies in hepatitis C and has authored over 300 peer-reviewed publications. He serves as one of the founding members of the US National hepatitis C treatment guidance panel. He is a Fellow of the American College of Physician (FACP), Infectious Diseases Society of America (FIDSA). He has received numerous awards including National Institute of Allergy and Infectious Diseases (NIAID) Meritorious service award for Innovations in Science (2014) and NIH Outstanding Mentor award (2013). Dr. Kottilil has mentored over 30 MDs and Ph.Ds during his academic career.
Hepatitis B, hepatitis C, HIV infection, T cell exhaustion
Kottilil S, Polis MA, Kovacs JA. HIV Infection, Hepatitis C infection, and HAART: Hard Clinical Choices. JAMA. (2004), 292:243-50.
Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, Kottilil S, Dybul M, Mican JM, Kovacs C, Chun TW, Birse CE, and Fauci AS. Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Super family. J Exp Med. (2004), 200:587-99.
Fauci AS Mavilio D, and Kottilil S. NK cells in HIV infection: Paradigm for Protection or Targets for Ambush. Nat Rev Immunol. (2005), 5: 835-43.
Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra T, Conrad TP, Lempicki RA, Cruz C, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode D, Fauci AS. The HIV-1 Envelope Binds to a4b7 integrin, the gut mucosal homing receptor. Nat Immunol. (2008), 9:301-309.
Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottilil S, Arthos J, Proschan MA, Chun TW, Fauci AS. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. (2008), 205:1797-805.
Kottilil S., Yan MY Reitano KN, Zhang X, Lempicki RA, Roby G, Daucher M, Yang J, Ghany M, Polis MA, and Fauci AS. HIV and HCV infections induce distinct immunologic imprints with implications for the pathogenesis of liver disease and therapeutic response to interferon-alpha. Hepatology (2009), 50:34-45
Hadigan C and Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA (2011), 306:294-301.
Naggie S, Osinusi A, Katsounas A, Lempicki RA, Herrmann E, Schlaak JF, Shivakumar B, Masur H, Polis MA, Kottilil S. Dysregulation Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With Depressed Viral Kinetics And Therapeutic Response. Hepatology (2012), 56:444-54.
Osinusi A, Meissner EG, Lee Y-J, ; Bon D, Heytens L, Nelson A, Sneller M, M.D. Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan K, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Ph.D, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian GM, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir And Ribavirin For Treatment Of Hepatitis C Genotype-1 In Patients With Unfavorable Treatment Characteristics: A Randomized Controlled Trial. JAMA (2013) 310:804-11.
Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S. Retreatment of HCV Genotype-1 with Sofosbuvir and Ledipasvir after Relapse with Sofosbuvir and Ribavirin: A Pilot Study. Annals Intern Med. (2014), 61(9):634-8.
Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J. Clin Invest (2014), 124(8):3352-63.
Kohli A, Sherman A, Kottilil S. HCV treatment Paradigms: A Systematic Review. JAMA (2014), Aug 13;312(6):631-40.
Meissner E, Osinusi A, Naggie S. Patel K, McHutchison J, Symonds W, Polis MA, Masur H, and Kottilil S. Effect of sofosbuvir and ribavirin on peripheral and hepatic lipid metabolism in chronic hepatitis C genotype 1 patients. Hepatology (2014), Mar;61(3):790-801.
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, M.S., Marti MM, Silk R, Kotb C, Gross C, Jolley T, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, M.D. Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Directly Acting Triple Drug Anti-HCV Therapy Induces Complete Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study. Lancet (2015), Mar 21;385(9973):1107-13
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferei G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polsi MA, Fauci AS, Masur H and Kottilil S. A Pilot Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in HCV Genotype 1 Subjects Coinfected with HIV Infection. JAMA (2015), Mar 24-31;313(12):1232-9
Kohli A and Kottilil S. Assessment of outcomes of Hepatitis C Treatment. JAMA (2014), Dec 17;312(23):2571
Osinusi A, Townsend K, Kottilil S, Virologic response to sofosbuvir and ledipasvir in HIV/HCV coinfected patients. JAMA (2015), 14;314(2):186-7
Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, and Kottilil S. Utility of HCV VL monitoring on Directly Acting Antoviral Therapy. Clin Infect Dis (2015), Jun 15;60(12):1743-51
Kottilil S., Wright M, Polis MA, Masur H, Treatment for Hepatitis C infection. Annals of Intern Med. (2015), Mar 17;162(6):459
Kohli A., Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang P, Osinusi A, Polis MA, Rustgi V, Masur H and Kottilil S. Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study. Lancet Infect Dis (2015), Sep;15(9):1049-54.
AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology (2015), Sep;62(3):932-54.
Tang L and Kottilil S. Treatment of HCV in HIV-infected patients: no longer a challenge? The Lancet HIV (2015), 2(8): e308-9
Kohli, A, Kattakuzhy S., Sidharthan S., Nelson A, McLaughlin M., Seamon C, Wilson E, Meissner EG, Sims Z, Silk R.; Gross C, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M.;Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Four-week Directly Acting Anti-HCV Regimens in HCV Genotype-1 Patients without Cirrhosis: A Phase 2a Cohort Study. Annals of Intern Med (2015), 163(12):899-907.
Wilson EM, Kattakuzhy S, Sidharathan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A and Kottilil S. Successful retreatment of chronic hepatitis C genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct acting antiviral regimens. The Clin Infect Dis, (2015) ;62(3):280-8.
Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Six-week Combination Directly Acting Anti-HCV Therapy Induces Moderate Rates of Sustained Virologic Response in Patients with Advanced Liver Disease. Clin Infect Dis. (2015), 62(4):440-7.
Emmanuel B, Sidique N, Zhang X,Poonia B, Sneller MC, Kottilil S, Decline in Cellular Activation in non-B cells after Rituximab Treatment in Hepatitis C-Associated Mixed Cryoglobulinemia Vasculitis J Vir Hepatitis 2016 (in press).
Tang L, Masur J, Nelson A, Osinusi A, Kohli A, Polis MA, and Kottilil S.
Baseline Mental Health Disease and Hepatitis C: Impact on Sustained Virologic
Response and Adherence with Interferon-Free Therapy. W. J Gastroenterology 2016 (in press).
Wilson E, Rosenthal E, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Clin Microbiol Rev 2016 (in press).
His specific interests include pathogenesis of chronic viral infections and translational research to eradicating infections by targeting the virus and the host.
He has received numerous awards including National Institute of Allergy and Infectious Diseases (NIAID) Meritorious service award for Innovations in Science (2014) and NIH Outstanding Mentor award (2013). Dr. Kottilil has mentored over 30 MDs and Ph.Ds during his academic career.
Member of the American Society of Clinical Investigation (ASCI) since 2017
American College of Physicians Richard and Hinda Rosnethal Award to that physician-scientist, clinician, or scientific group whose recent innovative work is making a notable contribution to improve clinical care in the field of internal medicine Recipient in 2019